Diligence memo · auto-generated · as of July 2, 2026
Neuralink Corp.
Neuralink Corp. looks over-valued against its niche peers and is active on financing cadence.
Businessfiled
Neuralink Corp. operates in Biotechnology, based in FREMONT. Creating a generalized brain interface to restore autonomy to those with unmet medical needs today and unlock human potential tomorrow.
Capital & rounds (filed)filed
Neuralink Corp. has raised $1.2B in disclosed capital across 5 recorded rounds, aggregated from public filings. Its latest round is modeled as Growth/Late (a round over $400M).
Largest single filing: $649M on 2025-05-30.
Most recent recorded round closed around 2025-05-30.
Valuation (modeled)modeled
Provath models Neuralink Corp. at approximately $6.4B (range $4.0B–$7.6B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 2.24× the median modeled value of Growth/Late Biotechnology companies in 2025–2027 (5 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 19 months.
Last raise 13 mo ago; this sector typically re-raises about every 14 months.
Raising on or ahead of the sector's normal rhythm.
The last round stepped up 2.0× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 100% of Biotechnology peers (4293 compared).
Modeled value ranks above 99% of those peers.
Closest niche peers: Eikon Therapeutics, Inc., Grail, Inc., Treeline Biosciences, Inc., Castle Creek Biosciences, Inc..
Peoplefiled
3 named people on file across officers, directors and signatories.
Risks & flagsmixed
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.